

Observations on the Impact of COVID-19 Disease on Oncology Practice from CancerLinQ®:

Aromatase Inhibitors and Tamoxifen

May 20, 2020

George Komatsoulis, PhD

Chief of Bioinformatics

These reports on the impact of COVID-19 on the practice of oncology are drawn from de-identified CancerLinQ data, collected to support quality improvement at our subscribing practices. For more information, see <https://cancerlinq.org/>. For feedback or questions, contact info@cancerlinq.org. This data is accurate as of 5/20/20, but there can be latency in reporting, and we will update it as new data becomes available.

Figure 1 shows the number of patients with drug orders or administration events for oral therapies used in breast cancer at the 35 practice sites that provide incremental updates. Weeks 1 and 53 have fewer than 7 days and that the final entry (week 20) for 2020 is for an incomplete week with only 4 days.

Aromatase Inhibitors and Tamoxifen




Figure 1: Number of patients with new prescription orders or administration events recorded in the EHRs of sites for the specified drug by week for selected agents (blue = 2019, orange = 2020)